S2S is a relaunch of University Research and Entrepreneurship Symposium (URES), an annual event from 2006-2013 that quickly became a seminal conference for the biotech community. Over the 6 years, investigators from universities including Boston University, Brown, Carnegie Mellon, Columbia, Cornell, Dartmouth, Harvard, Johns Hopkins, MIT, NYU, Purdue, Rensselaer Polytechnic, Tufts, UCLA, University of Kansas, University of Pennsylvania, University of Wisconsin, Yale, and more, presented their startup ideas to entrepreneurs and venture capitalists.
Who and What to Expect
S2S is an invitation-only symposium featuring the most innovative startup ideas in therapeutics from top research institutions around the world. Presentations are accompanied by panel discussions and mentorship opportunities led by prominent entrepreneurs, investors, and industry business leaders.
WHEN AND WHERE
SUBMIT A PROPOSAL
The S2S submissions process is designed to select discoveries and technologies with the highest therapeutic potential and a tractable development path to proof of concept. Ideally, the program should have some form of proof of biology data and not be more than 2-3 year from the clinic. A one-page document addressing the topics listed below is required. Additional supportive documents are also welcomed. Please only submit non-confidential materials.
- Description of therapeutic approach
- Differentiation over existing/competitive approaches and the supporting data
- Near-term research plan (next 12 months) and resources required
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.
F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world's most significant challenges in healthcare and technology. For more information, please visit www.fprimecapital.com.
SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm. Our goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over $2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.